Yahoo! Finance: Biotechnology Industry News: Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R)

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R) Mar 28th 2013, 00:01 [GlobeNewswire] - THE WOODLANDS, Texas -- Repros Therapeutics Inc.(R) today reported top-line results for the first pivotal study of Androxal, ZA-301, in the treatment of secondary hypogonadism. Results for the Intent-to-Treat ...

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions